Clinical Trial Update: A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia [Phase 1]

View source ↗

Summary

This completed Phase 1 trial evaluated the impact of SEP-363856 versus prior antipsychotic standard of care on body-weight–related parameters in adults with sch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED